IMR Press / FBE / Volume 3 / Issue 2 / DOI: 10.2741/E280

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

CD133 negative cancer stem cells in glioblastoma
Show Less
1 Department of Neurology, RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen

*Author to whom correspondence should be addressed.


Front. Biosci. (Elite Ed) 2011, 3(2), 701–710;
Published: 1 January 2011

Glioblastomas (GBM) are paradigmatic for the investigation of cancer stem cells (CSC) in solid tumors. Recently, the discovery of CD133- CSC in addition to CD133+ CSC has substantially added to our understanding of the complexity of GBM CSC. This review gives an overview on our current knowledge on CD133- cells in GBM and describes five different hypothesizes on the nature of CD133- cells in GBM. In addition, we summarize the current knowledge on tumorigenic CD133- CSC, list available markers, describe the current controversies on the origin of CD133- CSC, and discuss how the heterogeneity of CSC may correspond to the molecular heterogeneity of GBM.

Cancer Stem Cell
Transcriptional Profile
Back to top